Daiichi Sankyo Worldwide

×

Publication

Authors Title Reference
Journal
Kumar A, Dudhal S, Sundari TA, Sunkara M, Usman H, Varshney A,Mukhopadhyay A. Dopaminergic-primed fetal liver mesenchymal stromal-like cells can reverse parkinsonian symptoms in 6-hydroxydopamine-lesioned mice. Chemotherapy 2016, 18, 307-319.
Raj VS, Barman TK, Kalia V, Purnapatre K, Dube S, Ramkumar G, Bhateja P, Mathur T, Chaira T, Upadhyay DJ, Surase YB, VenkataramananR, Chakrabarti A, Das B, Bhatnagar PK. A novel ketolide RBx-14255 with activity against multi-drug resistant Streptococcus pneumoniae. Antimicrob Agents Chemother. 2014, 58(8), 4283-4289.
Tandon R, Senthil V, Nithya D, Pamidiboina V, Kumar A, Malik S, Chaira T, Diwan M, Gupta P, Venkataramanan R, Malik R, Das B, Dastidar SG, Cliffe IA, Ray A, Bhatnagar PK. RBx-10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy. Eur J Pharmacol. 2013, 711(1-3), 19-26.
Srikanth CH, Chaira T, Sampathi S,Sreekumar VB, Bambal RB. Correlation of in vitro and in vivo plasma protein binding using ultracentrifugation and UPLC-tandem mass spectrometry. Analyst 2013, 138(20), 6106-6116.
Soni A, Rehman A, Naik K, Dastidar S, Alam MS, Ray A, Chaira T, Shah V, Palle VP, Cliffe IA, Sattigeri VJ. Synthesis and evaluation of 4,5-dihydro-5-methylisoxazolin-5-carboxamide derivatives as VLA-4 antagonists. Bioorg Med Chem Lett. 2013, 23(5), 1482-1485.
Singh RK, Tandon R, Dastidar SG, Ray A. A review on leukotrienes and their receptors with reference to asthma. J Asthma 2013, 50(9), 922-931.
Mathur T, Kalia V, Barman TK, Singhal S, Khan S, Upadhyay DJ, Rattan A, Raj VS. Anti-anaerobic potential of ranbezolid: insight into its mechanism of action against Bacteroides fragilis. Int J Antimicrob Agents. 2013, 41(1), 36-40.
Chakraborty S, Chopra P, Hak A, Dastidar SG, Ray A. Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis. Expert Opin Investig Drugs 2013, 22(4), 499-515.
Ruchi T, Gupta A, Ray A. Mechanism of action of anti-diabetic property of cinnamic acid, a principal active ingredient from the bark of Cinnamomum cassia. International Journal of Therapeutic Applications 2013, 9, 39-45.
Srivastava PK, Ray A. Phospholipase A2 in airway diseases: target for drug discovery. Journal of Drug Discovery and Therapeutics 2013, 1(8), 28-40.
Kumar R, Rathy S, Hajare AK, Surase YB, Dullu J, Jadhav JS, Venkataramanan R, Chakrabarti A, Pandya M, Bhateja P, Ramkumar G, Das B. Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens. Bioorg Med Chem Lett. 2012, 22(1), 476-481.
Kumar M, Mathur T, Barman TK, Ramkumar G, Bhati A, Shukla G,Kalia V, Pandya M, Raj VS, Upadhyay DJ, Vaishnavi C, Chakrabarti A, Das B, Bhatnagar PK. In vitro and in vivo activities of the novel Ketolide RBx-14255 against Clostridium difficile. Antimicrob Agents Chemother. 2012, 56(11), 5986-5989.
Singh RK, Gupta S, Tiwari P, Saini S, Malik R, Kant R, Dastidar SG, Ray A. A fluorescent based enzyme assay for recombinant human lipoxygenase enzyme isoforms. Pharmacologia 2012, 3(9), 387-396.
Vijayakrishnan L, Venkataramanan R,Gulati P. Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol Sci. 2011, 32(1), 25-34.
Tandon R, Kapoor S, Vali S, Senthil V, Nithya D, Venkataramanan R, Sharma A, Talwadkar A, Ray A, Bhatnagar PK,Dastidar SG. Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment. Eur J Pharmacol. 2011, 667(1-3), 56-65.
Soni A, Dutt A, Sattigeri V, Cliffe IA. Efficient and selective demethylation of heteroaryl methyl ethers in the presence of aryl methyl ethers. Synthetic Communications 2011, 41(12), 1852-1857.
Singh S, Roy S, Sethi S, Benjamin B, Sundaram S, Khanna V,Kandalkar SR, Pal C, Kant R, Patra AK, Rayasam G, Mittra S, Saini KS, Paliwal J, Chugh A, Ahmed S, Sattigeri J, Cliffe IA, Ray A, Bansal VS, Bhatnagar PK, Davis JA. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes. Eur J Pharmacol. 2011, 652(1-3), 157-163.
Mathur T, Kumar M, Barman TK, Kumar GR, Kalia V, Singhal S, Raj VS, Upadhyay DJ, Das B, Bhatnagar PK. Activity of RBx-11760, a novel biaryl oxazolidinone, against Clostridium difficile. J Antimicrob Chemother. 2011, 66(5), 1087-1095.
Khera MK, Cliffe IA, Mathur T, Prakash O. Synthesis and in vitro activity of novel 1,2,4-triazolo[4,3-a]pyrimidine oxazolidinone antibacterial agents. Bioorg Med Chem Lett. 2011, 21(10), 2887-2889.
Gupta S, Malhotra S, Sinha S, Singh SK, Singh RK, Krishna S, Chhabra P, Chaira T, Kannayiram J,Sharma P, Aeron S, Kaur J, Kumar N, Sattigeri J, Shirumalla RK, Paliwal J, Dastidar SG, Cliffe IA, Ray A, Bhatnagar P. Pharmacodynamic and pharmacokinetic profile of RBx-343E48F0: a novel, long acting muscarinic receptor antagonist. Eur J Pharmacol. 2011, 658(2-3), 219-228.
Barman TK, Rao M, Bhati A, Kishore K, Shukla G, Kumar M, Mathur T, Pandya M, Upadhyay DJ. Non invasive real-time monitoring of bacterial infection & therapeutic effect of anti-microbials in five mouse models. Indian J Med Res. 2011, 134(5), 688-695.
Rao M, Barman TK, Kumar M, Mathur T, Shukla G, Bhati A, Kishore K, Chaira T, Pandya M, Upadhyay DJ. Efficacy of linezolid against Staphylococcus aureus in different rodent skin and soft tissue infections models. Microbiology Research. 2011, 2(1), 10-13.
Sharma S, Misra CS, Arumugam S, Roy S, Shah V, Davis JA, Shirumalla RK, Ray A. Antidiabetic activity of resveratrol, a known SIRT1 activator in a genetic model for type-2 diabetes. Phytother. Res. 2011, 25(1), 67-73.
Khera MK, Cliffe IA, Mathur T, Prakash O. Synthesis and in vitro activity of novel 1,2,4-triazolo[4,3-a]pyrimidine oxazolidinone antibacterial agents. Part II. Bioorg Med ChemLett. 2011, 21, 5266-5269.
Tiwari P, Saini S, Upmanyu S, Benjamin B, Tandon R, Saini KS, Sahdev S. Enhanced expression of recombinant proteins utilizing a modified baculovirus expression vector. Mol Biotechnol. 2010, 46(1), 80-89.
Sinha S, Gupta S, Malhotra S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A, Ray A. AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder. Br J Pharmacol. 2010, 160(5), 1119-1127.
Singh RK, Gupta S, Dastidar S, Ray A. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology. 2010, 85(6), 336-349.
Singh D, Rani R, Rajendran R, Kaur NJ, Pandey A, Chopra P, Jain T, Jain MK, Grover S, Arya R, Saini KS. Human spleen tyrosine kinase (Syk) recombinant expression systems for high-throughput assays. Biotechnol J. 2010, 5(2), 201-212.
Rehman A, Soni A, Naik K, Nair S, Palle VP, Dastidar S, Ray A, Alam MS, Salman M, Cliffe IA, Sattigeri V. Synthesis and biological activity of N-substituted aminocarbonyl-1,3-dioxolanes as VLA-4 antagonists. Bioorg Med Chem Lett. 2010, 20(18), 5514-5520.
Pandya M, Chakrabarti A, Rathy S, Katoch R, Venkataraman R, Bhateja P, Mathur T, Kumar GR, Malhotra S, Rao M, Bhadauria T, Barman TK, Das B, Upadhyay, D, Bhatnagar PK. Activity of a novel series of acylides active against community-acquired respiratory pathogens. Int J Antimicrob Agents. 2010, 36(2), 169-174.
Miglani R, Cliffe IA, Voleti SR. Assessment of the putative binding conformation of a pyrazolopyridine class of inhibitors of MAPKAPK2 using computational studies. Eur J Med Chem. 2010, 45(1), 98-105.
Dube S, Nanda K, Rani R, Kaur NJ, Nagpal JK, Upadhyay DJ, Cliffe IA, Saini KS, Purnapatre KP. UDP-N-acetylglucosamine enolpyruvyl transferase from Pseudomonas aeruginosa. World J Microbiol Biotechnol. 2010, 26(9), 1623-1629.
Dev R, Srivastava PK, Iyer JP, Dastidar SG, Ray A. Therapeutic potential of matrix metalloprotease inhibitors in neuropathic pain. Expert Opin Investig Drugs 2010, 19(4), 455-468.
Chopra P, Sethi G, Dastidar S. G, Ray A. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert Opin Investig Drugs 2010, 19(1), 27-43.
Chopra P, Kulkarni O, Gupta S, Bajpai M, Kanoje V, Banerjee M, Bansal V, Visaga S, Chatterjee M, Chaira T, Shirumalla RK, Verma AK, Dastidar SG, Sharma G, Ray A. Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase. Int Immunopharmacol. 2010, 10(4), 467-473.
Khanna A, Raj VS, Tarai B, Sood R, Pareek PK, Upadhyay DJ, Sharma P, Rattan A, Saini KS, Singh H. Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. Antimicrob Agents Chemother. 2010, 54(11) 4789-4793.
Scientific Presentation
Ajay Soni, Subham Saha, Aditi Agarwal, Shelly Aeron, Manoj Das, Kalyankar Ravsaheb Shripati, Biswajit Das, Ian A. Cliffe, Ruchi Tandon, Rakesh Kumar Singh, Reenu Sodhi, Sunanda Ghosh Dastidar, Shashi Kant Singh, Sandeep Sinha, Raj Kumar Shriumalla, Vinod Prasad Semwal, Shinji Marumoto and Takahiro Nagayama. Design, synthesis and SAR of 2-acetamido-3-pyrrolidinepropanamide derivatives as urotensin-II receptor antagonists. 250th ACS National Meeting, Boston, MA, United States, 2015.

18th SCI/RSC Medicinal Chemistry Symposium, Cambridge, UK, 2015.
Rijwan Jaffer Momin, Lalima Sharma, Rakesh Kulkarni, Rajesh Verma, Shibu Verughese, Ajay Yadav, Rizwan Shaikh, Naresh Kumar, Jitendra A. Sattegeri and Ian A. Cliffe. Approaches for synthesis of diversly substituted thiazoles. 4th National Symposium on Recent Advances in Analytical Sciences and Applications. New Delhi, India, 2015.
Praful Gupta, Jyoti Dullu, Yogesh Khairnar, Pritam Saha, Rajesh Kumar, Asher Siddiqui, Ruchi Tandon, Senthil Ambi Visaga, Nithya D., Tridib Chaira, Anjan Chakrabarti, Biswajit Das, Sunanda G. Dastidar, Abhijit Ray, Ian A. Cliffe and R. Venkataramanan. Dual EGFR/ IGFR inhibitor: a novel approach to overcome resistance. 245th ACS National Meeting & Exposition, New Orleans, LA, United States, 2013.
Lalitha Vijayakrishnan, Sunanda G. Dastidar, Manish Diwan, Tridib Chaira, Gayathri Balakrishnan, Anushree Hak, Ankur Kumar, Venu Pamidiboina, Sumit Malik, Biswajit Das, R. Venkataramanan, Ajay S. Yadav, Praful Gupta, Mahesh S. Deshmukh, Jyoti Dullu, Shibu B. Varughese, Masayuki Ishizaki, Masatoshi Nagamochi, Shinji Tanaka, Mika Yokoyama, Kenichi Yoshida, Masato Tomii, Ian A. Cliffe, Abhijit Ray and Pradip Kumar Bhatnagar. Activity of potent, highly selective and ATP-competitive JAK3 inhibitors in a rodent model of inflammation and reticulocytopenia. 12th Annual Meeting of the American College of Rheumatology, Washington DC, USA, 2012.
Gayathri Balakrishnan,Lalitha Vijayakrishnan, Sunanda G. Dastidar, Raj Kumar Shirumalla, Vijay M.Kanoje, Manish Banerjee, Shweta Saxena, Nidhi Gupta, Sonali Rudra, Jitendra Sattigeri, Ian A. Cliffe, Pradip K. Bhatnagar and Abhijit Ray. Anti-inflammatory activity and airway neutrophil reductions in a mouse model of LPS induced neutrophilia mediated by a subtype selective PDE 4B inhibitor, RBx 424FEDE. International Symposium on Airway Diseases: Etiology to Clinic, Gurgaon, India, 2012.
Praful Gupta and Ian A. Cliffe. Design and synthesis of biologically active 5HT1A receptor ligands. International Conference on Global Trends in Pure and Applied Chemical Science, Udaipur, India, 2012.
Book / Book Chapter
Jitendra A. Sattigeri, Joseph A. Davis, Shahadat Ahmed, Vinay Bansal, Biju Benjamin, Pradip K. Bhatnagar,Satyanarayana M. Chilla,Dhrubajyoti Dutta, Balasaheb G. Jadhav, Garima Jain, Tarun Jain, Geetavani Rayasam, Sachin Sethi, Yogendra Singh, Kona S. Srinivas, Vamshi K. Tulasi, Sunitha Udupa, Sreedhara R. Voleti and Ian A. Cliffe. Approaches towards the development of a chimeric DPP4/ACE inhibitor for treating Metabolic Syndrome. In New Frontiers in Drug Design, Discovery and Development. Proceedings of the Seventeenth Annual Symposium. Jalali, R.K, Ed. Ranbaxy Science Foundation, Gurgaon, India, 2012.
Abhijit Ray and Punit Kumar Srivastava. Obstructive airway diseases: role of lipid mediators. USA: CRC Press, 2011.

Company Profile

As a global company, we aim to constantly extend our business activities.